MHB042C / Minghui Pharma - LARVOL DELTA

Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor (AACR 2025) - "GLP study in monkeys revealed a favorable safety profile with no off-target toxicities. The highest non-severely toxic dose (HNSTD) was determined to be 15 mg/kg Q3W, the maximum dose tested.In conclusion, MHB042C demonstrated potent antitumor activity both in vitro and in vivo, along with a favorable safety profile, supporting advancement to clinical development."

ADC • Preclinical • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

A Study of MHB042C in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

New P1/2 trial • Solid Tumor